| Title : Coincidental Onset of Ocular Myasthenia Gravis Following ChAdOx1 n-CoV-19 Vaccine against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) - Galassi_2022_Isr.Med.Assoc.J_24_9 |
| Author(s) : Galassi G , Rispoli V , Iori E , Ariatti A , Marchioni A |
| Ref : Isr Med Assoc J , 24 :9 , 2022 |
|
Abstract :
The Oxford-AstraZeneca vaccine ChAdOx1 (AZD1222, Vaxzevria) is playing a crucial role in counteracting the coronavirus disease-2019 (COVID-19) pandemic [1]. Since March 2021, reports of unexpected thrombotic events associated with thrombocytopenia and vaccination have been published [2]. To the best of our knowledge there is only one report about vaccination-associated myasthenia gravis (MG) occurring after a second dose of BNT162b2 (Pfizer-BioNTech). |
| PubMedSearch : Galassi_2022_Isr.Med.Assoc.J_24_9 |
| PubMedID: 35077038 |
Galassi G, Rispoli V, Iori E, Ariatti A, Marchioni A (2022)
Coincidental Onset of Ocular Myasthenia Gravis Following ChAdOx1 n-CoV-19 Vaccine against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Isr Med Assoc J
24 :9
Galassi G, Rispoli V, Iori E, Ariatti A, Marchioni A (2022)
Isr Med Assoc J
24 :9